Tegoprazan-Based Dual Therapy With Amoxicillin vs Tetracycline for H. Pylori Eradication

Launched by ZHONGSHAN HOSPITAL (XIAMEN), FUDAN UNIVERSITY · May 10, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for Helicobacter pylori (H. pylori) infection, which is a common cause of stomach problems. The researchers want to find out if a combination of a medication called tegoprazan, which helps reduce stomach acid, with either high-dose amoxicillin or tetracycline can effectively eliminate H. pylori in adults. The goal is to find a simpler and more tolerable treatment option compared to traditional therapies that can involve multiple medications and side effects.

To participate in this trial, you need to be between 18 and 65 years old and have been diagnosed with H. pylori infection. You should also have previously tried and failed at least two other treatments for this infection. Participants will take the study medications for a specific period and will be monitored for their effectiveness and any side effects. It’s important to note that people with certain health conditions or who are pregnant or breastfeeding cannot join this study. This trial aims to provide better treatment options for those struggling with H. pylori infection, helping to improve their health and quality of life.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age from 18 to 65 years;
• • 2. H.pylori infection diagnosed by 13C-urea breath test;
• • 3. The patient infected with Helicobacter pylori has never undergone eradication therapy.
• Exclusion Criteria:
• • 1. Allergy to any of the medications;
• • 2. Zollinger-Ellison syndrome, GC, Upper gastrointestinal bleeding, or Active peptic ulcer;
• • 3. Coexistence of significant concomitant illnesses, including heart disease, renal failure, hepatic disease, previous abdominal surgery, lactation, or pregnancy;
• • 4. Patients who had used PPI/P-CAB drugs, and antibiotics in the past 12 weeks;
• • 5. Unwillingness to participate in this study.